Previous 10 | Next 10 |
Guardant Health, Inc. (Nasdaq: GH) today announced it will report financial results for the third quarter 2020 after market close on Thursday, November 5, 2020. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern ...
Guardant Health, Inc. (Nasdaq: GH) (“Guardant Health”), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, announced today the closings of an underwritten public...
Investors have experienced years' worth of volatility in the past nine months. First, we witnessed the fastest descent into bear-market territory in history as the coronavirus pandemic took hold in March. Then, the market vaulted higher, even reaching brand-new highs in August. But in ...
Guardant Health (NASDAQ: GH) opened lower Wednesday after the company announced the pricing of shares being offered for public sale by SoftBank Investment Advisers, a unit of SoftBank Group . The Japanese technology conglomerate is offering 7 million shares of Guardant ...
Guardant Health, Inc. (Nasdaq: GH) (“Guardant Health”), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, announced today the pricing of an underwritten public ...
Electro-Sensors (ELSE) -24%.CleanSpark (CLSK) -24% after pricing equity offering.Asia Pacific Wire & Cable (APWC) -17%.RCM Technologies (RCMT) -13%.Ashford Hospitality Trust (AHT) -12% after shareholders OK issuance of up to 126M shares.Aytu BioScience (AYTU) -11%...
Guardant Health (GH) +1.1% PM, commenced a proposed underwritten public offering of 7M shares of its common stock being offered for sale by SoftBank Investment Advisers.Underwriters granted a 30-day option to purchase up to 700K additional shares.Guardant Health is not selling ...
Guardant Health, Inc. (Nasdaq: GH) (“Guardant Health”), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, announced today the commencement of a proposed underwr...
Nature Medicine Publication Reports that Liquid Biopsy More Than Doubles Clinical Trial Enrollment Rate Compared to Tissue Biopsy Guardant Health, Inc. (Nasdaq: GH). Despite advances in precision oncology, progress is slowed by the limitations of tissue genotyping, which is ...
Beating the market is no small feat, especially when we define the market as the Nasdaq. However, it's very possible so long as one equips themselves properly. In this note, I will share a handful of psychological tools, philosophies, and techniques with which one can equip themselves...
News, Short Squeeze, Breakout and More Instantly...
Shield is first blood test approved by FDA as a primary screening option for colorectal cancer and that meets performance requirements for Medicare coverage Blood test offers easy, convenient and pleasant screening option with potential for improving colorectal cancer screening rates ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Ti...
Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity Upgraded test covered ...